相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The Bcl-2 apoptotic switch in cancer development and therapy
J. M. Adams et al.
ONCOGENE (2007)
Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737
Stephen K. Tahir et al.
CANCER RESEARCH (2007)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer
Christine L. Hann et al.
TRENDS IN MOLECULAR MEDICINE (2007)
Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy
R. Kim et al.
CANCER GENE THERAPY (2007)
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group
Agop Y. Bedikian et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice
Jill Lacy et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes
Kazuki Yamanaka et al.
BJU INTERNATIONAL (2006)
Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature
EM Anderson et al.
CANCER GENE THERAPY (2006)
A review of first-line treatment for small-cell lung cancer
Nevin Murray et al.
JOURNAL OF THORACIC ONCOLOGY (2006)
G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice
V Gekeler et al.
OLIGONUCLEOTIDES (2006)
Therapeutic potential of Toll-like receptor 9 activation
Arthur M. Krieg
NATURE REVIEWS DRUG DISCOVERY (2006)
Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer
MM Mortenson et al.
LUNG CANCER (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts
M De Cesare et al.
EUROPEAN JOURNAL OF CANCER (2005)
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer
CM Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): A rational therapeutic to enhance apoptosis in therapy of lung cancer
RS Herbst et al.
CLINICAL CANCER RESEARCH (2004)
Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen)
A Raffo et al.
CLINICAL CANCER RESEARCH (2004)
Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment
S Hopkins-Donaldson et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein
NWCJ van de Donk et al.
LEUKEMIA (2003)
A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer
CM Rudin et al.
ANNALS OF ONCOLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Genetic analysis of chemoresistance in primary murine lymphomas
CA Schmitt et al.
NATURE MEDICINE (2000)
分享论文
